Abstract | OBJECTIVE: DESIGN: One-hundred and five HIV-1 infected adults with ADC were randomized to receive either ABC (600 mg twice daily) or ABC-matched placebo (twice daily) in addition to SBG for 12 weeks. METHODS: Plasma and CSF were collected for population sequencing at baseline and week 12 (CSF optional). Sequences were analyzed for mutations associated with resistance to nucleoside reverse transcriptase inhibitors (NRTI). RESULTS: Sixty out of sixty-seven subjects with baseline plasma HIV-RT sequence data harbored virus with > or = 1 NRTI-associated mutations; 50 out of 67 had the M184V mutation. At week 12, more subjects in the ABC group had plasma HIV-1 RNA < or = 400 copies/ml than the SBG group (46% versus 13%, P = 0.002). Non-response to ABC was associated with multiple baseline zidovudine (ZDV)/ stavudine (d4T)-associated mutations. Baseline RT mutation patterns differed in 14 out of 21 (67%) paired samples from plasma and CSF. Four subjects experienced > 1 log10 copies/ml reductions in CSF HIV-1 RNA, two in the absence of reductions in plasma HIV-1 RNA and two with undetectable plasma HIV-1 RNA at baseline. CONCLUSIONS: Substantial decreases in plasma and CSF HIV-1 RNA following addition of ABC were not precluded by baseline HIV-1 NRTI-associated mutations, including the M184V mutation, but non-responders commonly harbored multiple ZDV/ d4T-associated mutations. HIV-1 RNA responses and RT genotype appear to be discordant between CSF and plasma in some subjects.
|
Authors | E R Lanier, G Sturge, D McClernon, S Brown, M Halman, N Sacktor, J McArthur, J H Atkinson, D Clifford, R W Price, D Simpson, G Torres, J Catalan, K Marder, C Power, C Hall, C Romero, B Brew |
Journal | AIDS (London, England)
(AIDS)
Vol. 15
Issue 6
Pg. 747-51
(Apr 13 2001)
ISSN: 0269-9370 [Print] England |
PMID | 11371689
(Publication Type: Clinical Trial, Clinical Trial, Phase III, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Anti-HIV Agents
- Dideoxynucleosides
- RNA, Viral
- Reverse Transcriptase Inhibitors
- HIV Reverse Transcriptase
- abacavir
|
Topics |
- AIDS Dementia Complex
(drug therapy, enzymology)
- Adolescent
- Adult
- Aged
- Anti-HIV Agents
(therapeutic use)
- DNA Mutational Analysis
- Dideoxynucleosides
(therapeutic use)
- Double-Blind Method
- Genotype
- HIV Reverse Transcriptase
(blood, cerebrospinal fluid, genetics)
- HIV-1
(genetics)
- Humans
- Middle Aged
- RNA, Viral
(blood, cerebrospinal fluid)
- Reverse Transcriptase Inhibitors
(therapeutic use)
|